Andere talen Zevra Therapeutics, Inc.

Aandelen

ZVRA

US4884452065

Geschatte realtime Cboe BZX Andere beurzen 17:30:12 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,64 ^USD	+1,31%		+1,75%	-29,16%

28/03	Zevra Therapeutics, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
28/03	Transcript : Zevra Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024	13:30
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024	29/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	28/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	20/04
Zevra Therapeutics Metabolic Disorder Treatment Shows 'Meaningful Slowing of Disease Progression'	15/04
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting	15/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	12/04
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility	10/04
Zevra Therapeutics, Inc. Refinances Existing Debt with up to $100 million in Committed Capital under New Credit Facility	10/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	05/04
Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Posts Q4 Revenue $13.2M, vs. Street Est of $11.7M	28/03
Zevra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	28/03
Zevra Therapeutics Says Phase 2 Trial of Idiopathic Hypersomnia Treatment Fulfilled Objectives	27/03
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia	26/03
Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia	26/03
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	25/03
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024	18/03
North American Morning Briefing : Inflation Data -2-	12/03
Sector Update: Health Care Stocks Mixed Late Afternoon	04/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Zevra Therapeutics, Inc.

Aandelen

ZVRA

US4884452065

Andere talen

Filters